azelnidipine has been researched along with Atherogenesis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukumoto, Y; Ito, K; Nawata, J; Onoue, N; Shimokawa, H; Sugimura, K; Tada, T; Wang, H; Zhulanqiqige, D | 1 |
| Inoue, T; Komoda, H; Node, K | 1 |
| Fukumoto, Y; Hosoya, M; Nakajima, S; Noda, K; Ohashi, J; Shimokawa, H | 1 |
| Egashira, K; Gang, Z; Iwata, E; Miyagawa, M; Nakano, K; Ohtani, K; Sunagawa, K | 1 |
4 other study(ies) available for azelnidipine and Atherogenesis
| Article | Year |
|---|---|
Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Calcium Signaling; Cell Movement; Cells, Cultured; Dihydropyridines; Disease Models, Animal; Equipment and Supplies; Estrenes; Hypertension; Imidazoles; Inositol 1,4,5-Trisphosphate Receptors; Macrocyclic Compounds; Muscle, Smooth, Vascular; Oxazoles; Pyrrolidinones; Rats; Rats, Wistar; Signal Transduction; Tetrazoles; Type C Phospholipases | 2008 |
Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Azetidinecarboxylic Acid; Biomarkers; C-Reactive Protein; Calcium Channel Blockers; Deoxyguanosine; Dihydropyridines; Female; Humans; Hypertension; In Vitro Techniques; Inflammation Mediators; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Oxidative Stress | 2010 |
Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; Azetidinecarboxylic Acid; Azo Compounds; Blood Pressure; Body Weight; Calcium Channel Blockers; Coronary Vessels; Diabetes Mellitus, Experimental; Dihydropyridines; Drug Therapy, Combination; Imidazoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Models, Biological; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphorylation; Systole; Tetrazoles | 2012 |
Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Chemokine CCL2; Dihydropyridines; Disease Models, Animal; Dose-Response Relationship, Drug; Macaca fascicularis; Male; Mice; Mice, Knockout; Platelet-Derived Growth Factor; Random Allocation; Tunica Intima | 2008 |